Antoine Roquilly

 

I was nominated full Professor at the University of Nantes in 2018, and Associate-Professor at the University of Melbourne in 2022. Over the last decade, I developed complementary clinical and basic research in the field of pneumonia. Early during my medical curriculum, I focused my research on the prevention, diagnosis and treatment of HAP. I notably coordinated 8 multicenter academic clinical trials in the field of respiratory cares, and 3 industrial-sponsored trials (from phase 1 to phase 3 clinical trials). Since 2021, I am director of the team “Immunology and Infections” of the CIC Plurithématique. At the bench, I investigated the impact of inflammation on myeloid cell functions during pneumonia. During my postdoc in the department of microbiology and immunology of Melbourne University (2013-2015), I continued investigating SIRS-induced immune dysfunction. I demonstrated that tolerogenic DC induced CD4 Treg cells accumulation, increasing tolerance to pathogens in the lungs (Immunity 2017). In 2018, I was nominated full Professor of Anesthesiology and Intensive Care at the University of Nantes, and I became lab director of Team 6 of UMR1064 CR2TI (former EA3826) at the University of Nantes in January 2022. Since then, I successfully developed independent and original thinking, as demonstrated by the publication as corresponding authors / last authors of 8 original articles in the field of pneumonia since 2019 (Lancet Respir Med 2019, Nature Immunol 2020, Clin Infect Dis 2020 x 3, JAMA 2021, BMJ 2021, Immunity 2021, Annual Review of Immunology 2022, AJRCCM 2022). I thus gained an international recognition as demonstrated by the obtention of coordinators of major grants 3 ANRs since 2020 (700 k€), and of 1 European Horizon H2020 grant to develop immunotherapy for pneumonia (10 millions €, 2020-2024), and nomination as member of the editorial board of Frontiers Immunol since 2022. Number of publications 144, 56 on pneumonia, Invited seminar 25). H-Index 30.